



## *Press Release*

### **Granules India's Paracetamol API Facility completes U.S. FDA Inspection**

**Hyderabad, June 16, 2014:** Granules India Ltd., a fast growing pharmaceutical manufacturing Company, announced its Paracetamol facility successfully passed a U.S. FDA inspection without any 483 observations. The facility has the world's largest single API production line by volume.

Granules' four API facilities have successfully passed U.S. FDA inspections in the past 12 months. All of Granules' facilities including its finished dosage and PFI facility are approved by leading regulatory agencies including the U.S. FDA, EDQM, Health Canada and Korean FDA.

### **About Granules India Ltd.**

About Granules India Ltd.

(BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

#### **Contact:**

Gayatri Ganesh  
Genesis Burson-Marsteller  
+91 9703700884  
gayatri.ganesh@bm.com